TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis
Research output: Contribution to journal › Journal article › Research › peer-review
Documents
- TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis
Final published version, 1.7 MB, PDF document
Mutations in the epigenetic modifier TET2 are frequent in myeloid malignancies and clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of undetermined significance (CCUS). Here, we investigate associations between TET2 mutations and DNA methylation in whole blood in 305 elderly twins, 15 patients with CCUS and 18 healthy controls. We find that TET2 mutations are associated with DNA hypermethylation at enhancer sites in whole blood in CHIP and in both granulocytes and mononuclear cells in CCUS. These hypermethylated sites are associated with leukocyte function and immune response and ETS-related and C/EBP-related transcription factor motifs. While the majority of TET2-associated hypermethylation sites are shared between CHIP and in AML, we find a set of AML-specific hypermethylated loci at active enhancer elements in hematopoietic stem cells. In summary, we show that TET2 mutations is associated with hypermethylated enhancers involved in myeloid differentiation in both CHIP, CCUS and AML patients.
Original language | English |
---|---|
Article number | 6061 |
Journal | Nature Communications |
Volume | 12 |
Issue number | 1 |
Number of pages | 10 |
ISSN | 2041-1723 |
DOIs | |
Publication status | Published - 2021 |
Bibliographical note
Publisher Copyright:
© 2021, The Author(s).
Number of downloads are based on statistics from Google Scholar and www.ku.dk
ID: 282741750